Immunogenic polymorphism: its medical implications in biotherapies

Immunogenic polymorphism is an obstacle to transfusion, grafting, transplantation and even incompatible pregnancy. Within the framework of biotherapies based on the use of elements from the human body and expressing this immunogenic genetic diversity, the success of this therapy relies on

  • On the understanding of the mechanisms and markers involved in the immunization and rejection processes in order to define rules of compatibilityOn the
  • taking into account of the preferential geographical distribution of these markers identifying the population source of compatible donorsOn
  • a supply of cells

    • ,

  • taking into account

    • the data from the SHS on the cultural determinants of the donation of elements from the human body for therapeutic purposes for the "Other "
    • In the long term, consider bypassing the donation of human origin in favor of the production of blood cells in vitro


Projets

Clinical consequences of the genetic diversity involved in the immune response

Based on the data from the previous project, the main objective of this project is to define the biomarkers particularly involved in the phenomena of tolerance, inflammation and rejection in order to improve the diagnostic and therapeutic management of transfused, grafted or transplanted patients as well as their donor selection.